Trial Profile
Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Sep 2020
Price :
$35
*
At a glance
- Drugs Insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 14 Sep 2020 Status changed from active, no longer recruiting to completed.
- 17 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association